Incyte
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT02257619
Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
Completed
- Conditions
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 2544
- Registration Number
- NCT02252159
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
- First Posted Date
- 2014-07-01
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 444
- Registration Number
- NCT02178722
- Locations
- 🇺🇸
University of Connecticut Health Center Carole And Ray Neag Comprehensive Cancer Center, Farmington, Connecticut, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Greater Baltimore Cancer Center, Baltimore, Maryland, United States
INCB047986 in Rheumatoid Arthritis
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 3
- Registration Number
- NCT02151474
Study of Ruxolitinib in Colorectal Cancer Patients
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 396
- Registration Number
- NCT02119676
A Study of Ruxolitinib in Pancreatic Cancer Patients
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 86
- Registration Number
- NCT02119663
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 149
- Registration Number
- NCT02120417
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 76
- Registration Number
- NCT02119650
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 321
- Registration Number
- NCT02117479
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT02093429
© Copyright 2024. All Rights Reserved by MedPath